GNMX - ETF AI Analysis
Top Page
Corgi Genomics & Precision Medicine ETF (GNMX)
Rating:60Neutral
Price Target:―
Positive Factors
Improving Recent Performance
The ETF has shown solid recent gains over the past month and is up so far this year, indicating improving momentum.
Exposure to Growing Genomics and Precision Medicine Theme
The fund focuses on genomics and precision medicine companies, giving investors targeted access to a fast-evolving area of health care innovation.
Several Strongly Performing Top Holdings
Some of the larger positions, such as Illumina, Guardant Health, Revolution Medicines, and Moderna, have delivered strong year-to-date performance that supports the fund’s returns.
Negative Factors
High Sector Concentration in Health Care
Almost all of the ETF’s assets are in the health care sector, so a downturn in this industry could significantly hurt performance.
Heavy U.S. Market Focus
With nearly all holdings in U.S. companies, the fund offers limited geographic diversification and is highly tied to U.S. market conditions.
Several Weak or Lagging Top Holdings
Some major positions like Thermo Fisher, Alnylam Pharma, Vertex Pharmaceuticals, Genmab, and Ionis Pharmaceuticals have shown weak year-to-date performance, which can drag on overall returns.
GNMX vs. SPDR S&P 500 ETF (SPY)
AUM1.65M
RegionGlobal
Expense Ratio0.35%
Beta0.63
IssuerCorgi
Inception DateMay 06, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume93
30 Day Avg. Volume1,278
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
38.31Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering58
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNMX Summary
The Corgi Genomics & Precision Medicine ETF (GNMX) is a health care fund focused on companies using DNA and data to create next‑generation medical tests and treatments. It follows a genomics and precision medicine theme rather than a broad market index, investing in firms involved in gene editing, genetic testing, and personalized drugs. Well-known holdings include Thermo Fisher and Moderna. Someone might invest in GNMX for long-term growth potential from advances in genetic medicine and to get targeted exposure to this niche. However, the fund is concentrated in a single, high-risk sector and its price can be very volatile.
How much will it cost me?This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this is a specialized, actively managed fund focused on genomics and precision medicine companies.
What would affect this ETF?This genomics and precision medicine ETF could benefit if new DNA-based tests and targeted treatments from companies like Thermo Fisher, Vertex, and Moderna gain wider medical acceptance, if healthcare systems increase spending on advanced diagnostics, and if supportive drug-approval policies encourage innovation globally. On the other hand, it could be hurt by tighter drug pricing rules, clinical trial setbacks at smaller biotech holdings, shifts in healthcare budgets away from high-cost therapies, or market pullbacks that hit high-growth health care stocks especially hard.
GNMX Top 10 Holdings
GNMX is firmly planted in the genomics and precision medicine world, with nearly all its firepower in healthcare names across the U.S. and a few global players. Illumina and Guardant Health have been the fund’s spark plugs lately, rising on renewed optimism around sequencing and liquid biopsy testing. Revolution Medicines and Moderna are also climbing, adding some high-octane, higher-risk biotech exposure. On the other side, Alnylam has been lagging, acting as a bit of a brake. Overall, the ETF leans heavily into cutting-edge genomic tools and therapies, making it a focused, volatile bet on the future of medicine.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Thermo Fisher | 9.28% | $151.62K | $213.42B | 23.03% | 72 Outperform | |
| Vertex Pharmaceuticals | 6.75% | $110.21K | $121.09B | -0.33% | 78 Outperform | |
| Illumina | 4.56% | $74.45K | $31.03B | 101.30% | 71 Outperform | |
| Guardant Health | 4.26% | $69.49K | $21.74B | 259.42% | 61 Neutral | |
| Revolution Medicines | 3.92% | $63.95K | $39.87B | 390.72% | 52 Neutral | |
| Incyte | 3.38% | $55.22K | $24.23B | 51.76% | 81 Outperform | |
| ― | 3.25% | $53.06K | ― | ― | ― | |
| Moderna | 3.06% | $50.05K | $21.75B | 99.49% | 59 Neutral | |
| Genmab | 2.96% | $48.27K | $17.12B | 30.48% | 76 Outperform | |
| Alnylam Pharma | 2.77% | $45.21K | $27.50B | -47.48% | 60 Neutral |
GNMX Technical Analysis
Positive
―
Price Trends
28.93
Positive
Market Momentum
0.22
Positive
56.69
Neutral
55.10
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNMX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.34, equal to the 50-day MA of 28.93, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 56.69 is Neutral, neither overbought nor oversold. The STOCH value of 55.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNMX.
GNMX Peer Comparison
Comparison Results
Performance Comparison
GNMX
Corgi Genomics & Precision Medicine ETF
30.55
5.26
20.80%
FDCF
Fidelity Disruptive Communications ETF
―
―
―
CSNR
Cohen & Steers Natural Resources Active ETF
―
―
―
HECO
SPDR Galaxy Hedged Digital Asset Ecosystem ETF
―
―
―
FITZ
Fitz-Gerald Must Have Portfolio ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents